Evidence-based recommendations for the use of WBC-reduced cellular blood components

Transfusion. 2001 Oct;41(10):1310-9. doi: 10.1046/j.1537-2995.2001.41101310.x.

Authors

T A Ratko¹, J P Cummings, H A Oberman, K P Crookston, P J DeChristopher, D T Eastlund, J E Godwin, R A Sacher, D H Yawn, K A Matuszewski; University Health System Consortium

Affiliation

¹ Technology Assessment Group, Clinical Practice Advancement Center, University Health System Consortium, Oak Brook, Illinois 60523-1890, USA. ratko@uhc.edu

PMID: 11606834
DOI: 10.1046/j.1537-2995.2001.41101310.x

No abstract available

Publication types

Consensus Development Conference
Guideline
Practice Guideline
Review

MeSH terms

Blood Component Transfusion / adverse effects
Blood Component Transfusion / methods
Blood Component Transfusion / standards*
Blood Preservation
Cost-Benefit Analysis
Evidence-Based Medicine*
Humans
Leukapheresis* / economics
Leukapheresis* / methods
Leukapheresis* / standards
Risk Assessment
United States
United States Food and Drug Administration / legislation & jurisprudence
Universal Precautions